Dr. Tew Evaluates Avastin Treatment in Ovarian Cancer

Video

William P. Tew, MD, a Gynecologic Medical Oncologist at Memorial Sloan-Kettering Cancer Center in New York, evaluates bevacizumab (Avastin) as a treatment for women with ovarian cancer

William P. Tew, MD, a Gynecologic Medical Oncologist at Memorial Sloan-Kettering Cancer Center in New York, evaluates the angiogenesis inhibitor bevacizumab (Avastin) as a treatment for women with ovarian cancer, at the 2010 ASCO Annual Meeting.

Related Videos
Elias Jabbour, MD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Debu Tripathy, MD
Sunil Iyer, MD
Zeynep Eroglu, MD
Zeynep Eroglu, MD
Yang Yang Hartwich, PhD
Manmeet Singh Ahluwalia, MD
John Paul Diaz, MD
Scott Kopetz, MD, PhD, FACP
Related Content
John Friend, MD

EVT801 Is Well Tolerated, Elicits Disease Control in Advanced Ovarian Cancer

May 1st 2024
Article
Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

January 11th 2024
Podcast
FDA

FDA Approves Tisotumab Vedotin for Recurrent or Metastatic Cervical Cancer

April 29th 2024
Article
R. Wendel Naumann, MD

Naumann Discusses Notable Research Efforts in Endometrial Cancer

October 26th 2023
Podcast
Sara Corvigno, MD, PhD

Understanding Chemotherapy-Related Clonal Hematopoiesis in Ovarian Cancer

April 27th 2024
Article
Shannon N. Westin, MD, MPH, FACOG

DENALI Study Seeks to Prove Efficacy of Azenosertib in High-Grade Serous Ovarian Cancer

April 26th 2024
Article